MS-2495

MS-2495

Samantha is a 72-year-old woman with rheumatoid arthritis. The disease has resulted in significant disability and is not fully controlled by her current drug regimen. Therefore, Samantha’s rheumatologist enrols her a trial of a new medication known as anakinra. She explains that this medication inhibits the action a cytokine known as interleukin-1 (IL-1) which helps stimulate inflammation. By inhibiting IL-1 this medication should improve Samantha’s symptoms.

Where does the main source of this cytokine come from?